Back to search results

Study of HB-adMSCs for Acute Kidney Injury

This study is looking at whether a treatment called Allogeneic HB-adMSCs can help prevent acute kidney injury (AKI) from getting worse after a trauma. AKI is when your kidneys suddenly stop working well. Researchers want to see if Allogeneic HB-adMSCs are safe and effective compared to a placebo (normal saline solution). You might be able to join if you are 18-75 years old, have been diagnosed with a specific stage of AKI (Modified KDIGO Stage 2) within 10 days of an injury, and are in the Intensive Care Unit or Intermediate Medical Unit. The study will look at how many infusion-related side effects occur and how long AKI lasts. The current status of this study is unclear.

Study design
This is a multicenter, randomized, double-blind, placebo-controlled study with a planned enrollment of 70 participants. It is a Phase 1/Phase 2a clinical study.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for infusion-related adverse events or serious adverse events for 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06654193

Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

Recruiting
PHASE1Ages 18–75InterventionalTreatment
Hope Biosciences LLC
~70 participants
Updated 2026-03-04 on ClinicalTrials.gov
What's tested:Allogeneic HB-adMSCsNormal Saline

At a glance

Recruiting sites
1 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of infusion-related adverse events (AEs) or serious adverse events (SAEs)
Measured over 1 year
+1 more outcome measured

Conditions

Acute Kidney Injury

Explore related trials

Acute Renal Failure

Where it's being run

3 sites across 3 states
Alabama1
California1
Texas1

Study leadership

  • Charles S Cox, Jr., MD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center, Houston

Who to contact

Charles S Cox, Jr., MD
[email protected]
713-500-7307
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of infusion-related adverse events (AEs) or serious adverse events (SAEs)1 year

    Incidence of treatment-related adverse events (TEAEs) will be monitored to assess the safety of the infusion product on the patients in Phase 1 of the trial.

  • Duration of Acute Kidney Injury (AKI) at Stage 22 days

    Proportion of patients with a duration of Stage 2 AKI more than 2 days after the start of treatment